Combined Transcriptomic–1H NMR Metabonomic Study Reveals That Monoethylhexyl Phthalate Stimulates Adipogenesis and Glyceroneogenesis in Human Adipocytes by Ellero-Simatos, Sandrine et al.
Published: October 21, 2011
r2011 American Chemical Society 5493 dx.doi.org/10.1021/pr200765v|J. Proteome Res. 2011, 10, 5493–5502
ARTICLE
pubs.acs.org/jpr
CombinedTranscriptomic
1HNMRMetabonomicStudyRevealsThat
Monoethylhexyl Phthalate Stimulates Adipogenesis and
Glyceroneogenesis in Human Adipocytes
Sandrine Ellero-Simatos,
†,‡ Sandrine P. Claus,
§ Chantal Benelli,
# Claude Forest,
# Franck Letourneur,
^
Nicolas Cagnard,
|| Philippe H. Beaune,
† and Isabelle de Waziers*
,†
†INSERM, UMR 775, Universit  e Paris Descartes, Sorbonne Paris Cit  e, 45 rue des Saints P  eres, 75006 Paris, France
‡AgroParisTech, ENGREF, 19 avenue du Maine, 75732 Paris, France
§Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, U.K.
#INSERM, UMR 747, Universit  e Paris Descartes, Sorbonne Paris Cit  e, 75006 Paris, France
^Plate-forme g  enomique Institut Cochin, Universit  e Paris Descartes, Sorbonne Paris Cit  e, 27 rue du faubourg Saint Jacques,
75014 Paris, France
)
INSERM/IRNEM-IFR94, Universit  e Paris Descartes, Sorbonne Paris Cit  e, H^ opital Necker, 149 rue de S  evres, 75015 Paris, France
b S Supporting Information
’INTRODUCTION
White adipose tissue (WAT) is one of the major contributors
to energy homeostasis in humans. Since lipids contribute 70% of
WAT, this tissue is also a major reservoir for lipophilic con-
taminants, which might interfere with the diﬀerentiation, meta-
bolism, and secretory functions of adipocytes.
1 Exposure to an
increasing number of chemicals is suspected to play a role in the
development of the obesity epidemic, and the environmental
obesogen concept was introduced recently.
2 In this context,
some environmentalpollutants are ofparticular concernbecause
they interfere with nuclear receptors controlling the expression
of genes involved in energy homeostasis such as those encoding
theperoxisomeproliferator-activatedreceptors(PPARs).PPARγ,
the dominant PPARisoforminhumanWAT,isan idealtargetfor
theseso-calledmetabolicdisruptors,sinceitregulateslipidstorage,
induces adipocyte diﬀerentiation and survival, and contributes to
control insulin sensitivity.
3
Phthalate esters are industrial chemicals used as plasticizers to
improve the pliability of PVC products. Di(2-ethylhexyl) phtha-
late (DEHP), the most widely used of the phthalate esters, is
found in ﬂexible plastics of a wide variety of common products
such as medical devices, cosmetics, industrial paints, solvents, or
food packaging. DEHP is not covalently bound to its matrix and
its propensity to leak can lead to high levels of human exposure.
After ingestion, intestinal lipases convert DEHP into its monoester
derivative monoethylhexyl-phthalate (MEHP), which is then
preferentially absorbed.
4 MEHP can also originate from the
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ABSTRACT: Adipose tissue is a major storage site for lipophilic environmental
contaminants. The environmental metabolic disruptor hypothesis postulates that
some pollutants can promote obesity or metabolic disorders by activating nuclear
receptors involved in the control of energetic homeostasis. In this context, mono-
ethylhexylphthalate(MEHP)isofparticularconcernsinceitwasshowntoactivatethe
peroxisome proliferator-activated receptor γ (PPARγ) in 3T3-L1 murine preadipo-
cytes.Inthepresentwork,weusedanuntargeted,combinedtranscriptomic-
1HNMR-
based metabonomic approach to describe the overall eﬀect of MEHP on primary
cultures of human subcutaneous adipocytes diﬀerentiated in vitro. MEHP stimulated
rapidly and selectively the expression of genes involved in glyceroneogenesis,
enhanced the expression of the cytosolic phosphoenolpyruvate carboxykinase, and
reduced fatty acid release. These results demonstrate that MEHP increased glycer-
oneogenesis and fatty acid reesteriﬁcation in human adipocytes. A longer treatment
with MEHP induced the expression of genes involved in triglycerides uptake, synthesis, and storage; decreased intracellular lactate,
glutamine, and other amino acids; increased aspartate and NAD, and resulted in a global increase in triglycerides. Altogether, these
results indicate that MEHP promoted the diﬀerentiation of human preadipocytes to adipocytes. These mechanisms might
contribute to the suspected obesogenic eﬀect of MEHP.
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conversion of DEHP by plasmatic or hepatic lipases. In vitro
trans-activation studies have shown that MEHP can activate the
three isoforms of PPAR receptors in human and murine cell
lines.
5 Furthermore, it has also been demonstrated that, in the
murine 3T3-L1 preadipocyte cell line, MEHP activated PPARγ
and promoted adipose cell diﬀerentiation (adipogenesis).
6 Con-
sequently, MEHP has been considered as a potential obesogen
and metabolic disruptor.
7 However, the eﬀects of MEHP on
human WAT remain unknown.
Understanding the eﬀects of pollutants in humans raises
complexchallenges.Extrapolationfromanimalmodelsisdiﬃcult
and depends on the conservation of the underlying molecular
mechanisms of action between species. Regarding PPAR activa-
tors in general, and for DEHP and MEHP in particular, these
molecular mechanisms have been shown to diﬀer greatly
betweenrodentmodelsandhumans.Inrodents,PPARactivators
induce sustained hepatic peroxisome proliferation mediated by
PPARα, which is likely to inﬂuence the metabolic phenotype of
these animals.
8 This phenomenon does not occur in humans.
MicetreatedwithDEHPareprotectedfromweightgaininduced
by a high fat diet, but this phenomenon is reversed in mice
expressing the human PPARα.
9 These results clearly demon-
strate that the eﬀects of DEHP on WAT can be species-speciﬁc
and emphasize the importance of using human models to
investigate its mechanisms of action.
Invivo,humansubcutaneousWATisconstitutedofamajority
ofmatureadipocytesrepresentingmorethan50%ofthetotalcell
count, surrounded by other cell types constituting the stroma-
vascular fraction, among which ﬁbroblasts and preadipocytes.
10,11
In the present work, we investigated the eﬀects of MEHP on
primaryculturesofhumanadipocytes,whichwerediﬀerentiatedin
vitro for 11 days. The cultures contained about 30% of preadipo-
cytes and a majority of mature adipocytes. The perturbations
induced by MEHP in human adipocytes diﬀerentiated in vitro
were described using an untargeted systems biology approach
combining transcriptomics and
1H NMR-based metabonomics at
several time points. We found evidence that MEHP activated two
diﬀerentmetabolicpathwaysinhumanadipocytesdiﬀerentiatedin
vitro, namely, glyceroneogenesis and adipocyte diﬀerentiation,
thereby increasing triglyceride content.
’EXPERIMENTAL PROCEDURES
Cell Culture
Primary cultures of human preadipocytes were provided by
Promocell (www.promocell.com) and originated from the sub-
cutaneousadiposetissueofﬁvehealthy women,aged36(5and
with a BMI < 28 kg/m
2. Preadipocyte growth and in vitro
diﬀerentiation into adipocytes were conducted according to
the provider’s recommendations. Brieﬂy, preadipocytes were
grown in Promocell Preadipocyte Growth Medium containing
5% fetal calf serum, 1 μg/mL hydrocortisone, 10 ng/mL human
recombinant growth factor, and 4 μL/mL heparin, until con-
ﬂuence(day0).Diﬀerentiationintoadipocyteswastheninduced
using Promocell Preadipocyte Diﬀerentiation Medium contain-
ing 3 μg/mL ciglitazone, 8 μg/mL biotin, 400 ng/mL dexa-
methasone, 44 μg/mL 3-isobutyl-1-methylxanthine, 0.5 μg/mL
insulin, and 9 ng/mL thyroxine for 3 days (until day 3). Dif-
ferentiation was pursued for 8 days in Promocell Adipocyte
Nutrition Medium containing 3% fetal calf serum, 8 μg/mL
biotin,400ng/mL dexamethasone, and 0.5 μg/mL insulin (until
day 11). On day 11, about 70% of the cells were diﬀerentiated
into adipocytes and about 30% remained undiﬀerentiated.
Cell Treatment
On day 11, the cells were treated with 100 μM MEHP
(Interchim, Montluc -on, France) dissolved in DMSO (ﬁnal
concentration 0.1%). This concentration was chosen based on
previous ﬁndings of the literature because it induced maximal
activation of the human PPARγ.
5 To minimize variations due to
cell culture conditions, cells from the ﬁve primary cultures were
grown and treated in parallel for the transcriptomic and meta-
bonomic analyses. Each primary culture was divided between
twoT75ﬂasks:onewasusedforRNAextractionandsubsequent
transcriptomicproﬁlingandtheother forcellpelletrecoveryand
subsequent metabolic proﬁling. For all other complementary
experiments, the same ﬁve primary cultures were used.
Transcriptomics and Data Analysis
At 24 h of treatment, total RNA was prepared as previously
described.
12RNAqualitywasveriﬁedonanAgilentBioanalyzeur
2100. Hybridization, cleaning, and scanning of Human Gene 1.0
ST microarrays were performed according to the manufacturer’s
instructions (Aﬀymetrix Inc., www.aﬀymetrix.com) on the geno-
mic platform of the Cochin Institute.
Data were normalized using Robust Multi-Array Average
expressionmeasure(RMA)Bioconductorpackageimplemented
on R (www.bioconductor.org). Log2 normalized data were
analyzed using the signiﬁcant analysis of microarray (SAM)
paired test (http://www-stat.stanford.edu/∼tibs/SAM/).
13 SAM
gives a list of signiﬁcantly regulated genes and estimates the false
positiverate.Forthedatapresentedinthisstudy,thefalsediscovery
rate was limited to 5%.
Gene ontology analyses were conducted using the bioinfor-
matics tool DAVID (http://david.abcc.ncifcrf.gov:8080/). A
combination of an enrichment score of 2 and a corrected p value
< 0.05 was considered signiﬁcant. We also used the link
betweenDAVIDandtheKEGGmetabolicdatabase(http://
www.genome.jp/kegg/pathway.html) and selected the pathways
that had a p value < 0.05. For more details on DAVID, see ref 14.
1H NMR Metabonomics and Data Analysis
At 24 or 48 h of treatment, cells were trypsinized at room
temperatureandwashedtwiceinphosphatebuﬀersalinebeforethe
cell pellet was frozen at 80  C. Polar and lipophilic metabolites
were extracted from the cell pellets using a chloroform/methanol/
water (2:1:3) mixture as described previously.
15 The supernatant
containingtheaqueousphasewastaken,freeze-dried,anddissolved
in 50 μLo fp h o s p h a t eb u ﬀe r0 . 2M( p H7 . 4 )i nD 2O plus 0.001%
TSP and transferred to microcapillary tubes. The inferior chloro-
form phase was taken, dried, and dissolved in 100 μLo fC D C L 3
plus 0.01% TMS and transferred to microcapillary tubes.
All spectra were acquired on a Bruker Avance 600 MHz
spectrometer (Bruker Analytische GmbH, Rheinstetten,
Germany), operating at 600.13 MHz, with a spectral width of
12000 Hz. For aqueous phases, spectra were acquired with a
standard one-dimensional sequence [relaxation delay-90 -t1-
90 -tm-90 -acquire free induction decay], with a water presa-
turation applied for 2 s and a mixing time (tm) of 100 ms and a
90  pulse length of 10 μs, using 512 scans and 64K data points.
For organic phases, spectra were acquired with a standard 1D
sequence with a relaxation delay of 3 s and a 90  pulse length of
3μs,using16scansand32Kdatapoints.TheFIDsweremultiplied
by an exponential function corresponding to 0.3 Hz line5495 dx.doi.org/10.1021/pr200765v |J. Proteome Res. 2011, 10, 5493–5502
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broadening. All spectra were manually phased, baseline cor-
rected,andcalibratedtoTSP(δ0.00).Metaboliteswereassigned
using previously published data
16,17 and additional two-dimen-
sional NMR experiments on selected samples.
To eliminate the variability in water resonance presaturation,
the chemical shift region between δ4.66 and 4.88 was removed
from all spectra prior to statistical analysis. As previously
described,
18 all data were analyzed on full-resolution spectra
(33600 data points), and aqueous phase spectra were normal-
ized to the total peak area. Despite the use of phosphate buﬀer
(pH 7.2), many aqueous phase spectra still displayed subtle
shifts. These diﬀerences were corrected using an alignment
function.
19 For organic phase spectra, the peak area for each
signal was integrated (13 peaks). The resulting peak area proﬁle
was normalized to a constant sum of the peak area for the two
cholesterol signals (δ0.9 and 1.1).
1H NMR proﬁles from aqueous phases were mean-centered
and scaled to unit variance, and
1H NMR proﬁles from organic
phases were mean centered prior to analysis using Matlab
software version R2009a (The MathWorks Inc.).
1H NMR
proﬁles were analyzed using orthogonal projection on latent
structure-discriminant analysis (O-PLS-DA), where
1H NMR
datawereusedasindependentvariables(Xmatrix)andregressed
againstadummymatrix(Ymatrix)indicatingtheclassofsamples
(DMSOorMEHP).
20AllO-PLS-derivedmodelswereevaluated
for goodness of prediction (Q
2Y value) using 5-fold cross-
validation. The reliability of each model was established using a
permutationtest oftheYvector (1000permutations)inorderto
determine a p value for each Q
2Y, as previously described.
21 To
identify metabolites responsible for discrimination between
MEHP- and DMSO-treated cells, the O-PLS-DA correlation
coeﬃcients(r
2)werecalculatedforeachvariableandback-scaled
into a spectral domain, so that the shape of NMR spectra and
the sign of the coeﬃcients were preserved.
18 The weights of
the variables were color-coded, according to the square of the
O-PLS-DA correlation coeﬃcients. Correlation coeﬃcients ex-
tracted from signiﬁcant models were ﬁltered so that only
signiﬁcant correlations above the threshold deﬁned by Pearson’s
critical correlation coeﬃcient (P < 0.05; r
2 = 0.38 when n = 10)
were considered signiﬁcant.
Determination of Intracellular Triglycerides
Human preadipocytes from the same ﬁve women were diﬀer-
entiatedinvitrofor11daysbeforetreatmentwith100μMMEHP
or 0.1% DMSO for 24 or 48 h. At day 0, day 3, day 6, day 9, and
day 11 of diﬀerentiation, as well as after 24 and 48 hof treatment
withMEHPorDMSO,cellswere trypsinized,washedtwicewith
PBS, suspended in 100 μL of PBS, and frozen at 80  C.
Intracellular triglycerides were measured using the “TG enzy-
matic PAP 150” kit from Biom  erieux (Marcy l’Etoile, France)
and normalized to protein content determined using the
bicinchonic acid method (Pierce biotechnology, Rockford, IL).
Each measurement was performed in triplicate.
Real Time Quantitative PCR (RT-QPCR)
Human preadipocytes from the same ﬁve women were
diﬀerentiated in vitro for 11 days before treatment with MEHP
100 μM or DMSO 0.1% for 4, 8, or 24 h. Total RNA extraction
wasperformedasforthetranscriptomicstudy.Reversetranscrip-
tion, RT-QPCR and data analysis were performed as previously
described
12 using primers described in Supplemental Table 1,
Supporting Information and RPL13A as housekeeping gene.
Western Blot
Human preadipocytes from the same ﬁve women were diﬀer-
entiatedinvitrofor11daysbeforetreatmentwith100μMMEHP
or 0.1% DMSO for 18 h. Proteins were extracted using RIPA
buﬀer according to the manufacturer’s instructions (Santa-Cruz
Biotechnology, Heidelberg, Germany). Cell lysates were centri-
fuged for 15 min at 14000g and 4  C to retrieve the cytosol.
Western blotting with anti-PEPCK-C was conducted as de-
scribedpreviously,
22usingactinasaninternalstandardtoensure
the quantity of loaded protein.
DeterminationofNonesterifiedFattyAcids(NEFA)Released
in Culture Medium
Human preadipocytes from the same ﬁve women were dif-
ferentiated in vitro for 11 days before treatment with 100 μM
MEHP or 0.1% DMSO for 18 h. They were fasted for 3 h in
DMEM without glucose, containing 3% (w/v) fatty acid-free
bovine serum albumin, and then transferred in a Krebs Ringer
Bicarbonate buﬀer containing 5 mM pyruvate for 2 h. This
medium was collected and NEFA was measured using a colori-
metric method with the Free Fatty Acids Half-Micro Test kit
from Roche Diagnostics GmbH (Mannheim, Germany). Each
measurement was performed in triplicate.
’RESULTS
Transcriptomic Effects of MEHP on Human Adipocytes
To assess the eﬀects of MEHP on human WAT, primary
cultures of subcutaneous preadipocytes (n =5 )w e r ed i ﬀeren-
tiatedinvitrointoadipocytesfor11daysandtreatedwithMEHP
(100 μM) or with DMSO (vehicle, 0.1% ﬁnal). An untargeted
global proﬁling approach combining transcriptomics and
1H
NMR-based metabonomics was used, starting with transcrip-
tomic proﬁling at 24 h of treatment. Principal component
analysis (PCA) conducted on the entire transcriptomic proﬁle
clearly separated MEHP and DMSO-treated human adipocytes,
indicating that MEHP strongly modiﬁed gene expression
(Figure 1A). Using a paired SAM test, we selected 227 genes
signiﬁcantly diﬀerentially regulated between MEHP- and
DMSO-treated adipocytes: 142 upregulated and 85 downregu-
lated (Supplemental Table 2, Supporting Information). The
biologicalpathwaysmodulatedbyMEHPweretheninvestigated
using gene ontology analyses of the 142 upregulated transcripts
orofthe85downregulatedtranscriptsintheDAVID(Figure1B)
and KEGG databases (Figure 1C). The same gene ontology
analysis using all 227 genes together identiﬁed the same biolo-
gical pathways and is therefore not reported here.
The analysis of upregulated transcripts ﬁrst showed that the
most signiﬁcantly activated biological pathway was the “PPAR
signaling pathway” which contained 12 genes (p =3 10
7,
Supplemental Table 3, Supporting Information). This result
indicatedthatMEHPprobablyactivatedPPARγ,themosthighly
expressed PPAR isoform in WAT. MEHP treatment also
enhanced metabolic processes involved in lipid metabolism, as
illustrated by the following signiﬁcant terms in the gene ontology
analyses: “Carboxylic acid metabolic process” (p =2 . 7 10
4),
“F a t t ya c i db i o s y n t h e s i s ” (p =2 10
3), “Fatty acid binding”
(p =1 . 0 10
2), “Polyunsaturated fatty acid biosynthesis”
(p =1 . 7 10
2)a n d“Fatty acid metabolism” (p =1 . 9 10
2).
Finally, the analysis of down-regulated transcripts showed
that MEHP disrupted genes involved in cell shape and in
cellenvironment interactions, as indicated by the terms5496 dx.doi.org/10.1021/pr200765v |J. Proteome Res. 2011, 10, 5493–5502
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“Glycoprotein/secreted”(p=5.710
6),“Extracellularmatrix”
(p=8.910
3),and“Regulationoftheactincytoskeleton”(p=
5  10
2).
1H NMR Based Metabolic Profiling of MEHP-Treated Human
Adipocytes
The metabolic disruptions induced by MEHP in human
adipocytes were evaluated in the same cell cultures (n =5 )a t
24 and 48 h of treatment using
1H NMR proﬁling on both the
organic and the aqueous fractions of cell extracts. Metabolic
alterationsinducedbyMEHPtreatmentwereﬁrstinvestigatedin
thepolarextractsofhumanadipocytes(Figure2A).Toassessthe
diﬀerences between the metabolic proﬁles of MEHP- versus
DMSO-treated human adipocytes, we constructed O-PLS-DA
models at 24 and 48 h as described in Experimental Procedures.
The metabolic proﬁles of MEHP-treated adipocytes diﬀered
markedly from those of DMSO-treated cells, at both 24 h
(parameters of the O-PLS-DA performed with one predictive
component and one orthogonal component: R
2X = 0.63, R
2Y =
0.87, Q
2Y = 0.73, p = 0.001, Supplemental Figure 1, Supporting
Information) and 48 h of treatment (parameters of the O-PLS-
DA performed with one predictive component and one ortho-
gonalcomponent:R
2X=0.65,R
2Y=0.94,Q
2Y=0.73,p=0.009;
Figure 2B). The metabolites responsible for this discrimina-
tion were determined by computing their correlation coeﬃ-
cient (r
2) derived from the O-PLS-DA models (Supplementary
Table 4, Supporting Information). At both time points, MEHP-
treated adipocytes displayed lower intracellular levels of
lactate and of several amino acids, including valine, glutamine,
phenylalanine, and tyrosine, as well as higher levels of aspartate.
MEHP treatment also inﬂuenced the level of metabolites
involved in phospholipid metabolism, as indicated by higher
levels of phosphoethanolamine and choline, and lower levels of
glycerophosphocholine in MEHP-treated adipocytes. Finally,
NAD
+ and creatine levels were increased in MEHP-treated
adipocytes.
In the apolar organic cell extracts, signals from various
lipophilic molecules such as cholesterol, glycerol linked to
phospholipids and/or to triglycerides and fatty acids were
detected (Figure 2C). As most of these signals derived from
fatty acids (either free or esteriﬁed in triglycerides), the conven-
tionalmethod of normalization, dividingeachspectraldatapoint
bythetotalspectralarea,wasnotadequate.Forexample,aglobal
increase of triglyceride content in one group would be missed
using this method. Therefore,
1H NMR peaks were integrated
and normalized to cholesterol signals (δ0.68 and δ1.01). This
normalization resulted in a simpliﬁed data matrix containing 13
variables. At 24 h of treatment, no diﬀerence was observed
between MEHP- and DMSO-treated human adipocytes (Q
2Y
<0,datanotshown).At48hoftreatment,signiﬁcantdiﬀerences
wereobservedbetweentheorganicmetabolicproﬁlesofMEHP-
treated compared to DMSO-treated human adipocytes
(parameters of the O-PLS-DA performed with one predictive
component and two orthogonal components: R
2X = 0.93, R
2Y =
0.98, Q
2Y =0.68, p =0.03).The discrimination betweenMEHP-
andDMSO-treatedhumanadipocyteswasmainlyduetoahigher
level of the protons involved in fatty acid double bonds (δ5.35,
signal J, r
2 = 0.41, p = 0.046) in MEHP-treated adipocytes
(Figure 2D). Two of the three glycerol signals showed increases
of borderline signiﬁcance in MEHP-treated adipocytes (δ5.28,
signalI,r
2=0.26,p=0.13andδ4.33,signalH,r
2=0.29,p=0.1).
Assessment of Intracellular Triglyceride Content in Human
Adipocytes
The previous untargeted transcriptomic and metabonomic
observations demonstrated that MEHP signiﬁcantly disrupted
Figure 1. Transcriptomic eﬀectsofMEHP onhuman adipocytes. Human preadipocytes (n=5)were diﬀerentiated in vitro intoadipocytes for11days
and then treated with MEHP (100 μM) or DMSO (0.1%, vehicle) for 24 h. (A) PCA analysis was conducted using expression data from the entire
microarray (32322 probesets). Black: DMSO,red: MEHP. (B, C)Geneontology analyses wereconducted onthe 142 signiﬁcantly upregulatedand on
the 85downregulated transcripts, usingDAVID(B)and KEGG(C) databases. P<0.05 was used ascutoﬀforselecting signiﬁcantlyenriched biological
pathways.5497 dx.doi.org/10.1021/pr200765v |J. Proteome Res. 2011, 10, 5493–5502
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lipid metabolism in human adipocytes. However, using standard
1D NMR spectroscopy, the increase in glycerol signals was of
borderline signiﬁcance, and we were unable to diﬀerentiate
between the glycerol linked to phospholipids and the glycerol
linked to triglycerides. Therefore, in order to conﬁrm and reﬁne
the previous results, we measured the triglyceride concentration
using an enzymatic reaction at several stages of humanadipocyte
diﬀerentiation and after MEHP treatment (Figure 3).
Intracellular triglyceride accumulation increased linearly dur-
ing the in vitro diﬀerentiation protocol. Eleven days after the
hormonal induction of diﬀerentiation, triglyceride accumulation
reached its maximal level and the cells were then treated with
MEHP. At 24 h, the intracellular triglyceride content was not
aﬀectedbyMEHPtreatment.Incontrast,at48h,thetriglyceride
level was signiﬁcantly higher in MEHP-treated compared to
DMSO-treatedadipocytes (213.6(2.9μg/mgproteinvs.168.8
( 9.9 μg/mg protein, respectively, p = 0.02, Figure 3). These
results therefore conﬁrmed the increased glycerol signals high-
lighted by
1H NMR after 48 h of MEHP treatment.
Early Effects of MEHP on Human Adipocytes
Transcriptomic and metabonomic results were integrated
using untargeted statistical modeling (Supplemental Figure 2,
Supporting Information). Integration of transcriptomic and
metabonomic data at the same time point (24 h of treatment)
produced poor statistical models, as illustrated by the low
number of p values < 0.1 (p values in blue, Supplemental Figure
2, Supporting Information). In contrast, integration of metabo-
nomic proﬁles obtained at 48 h of treatment and transcriptomic
proﬁles at 24 h produced an overall shift of the p values toward
lower values, indicating stronger associations between these two
data sets (p values in red). This result demonstrated that the
metabolic alterations after 48 h of MEHP treatment correlated
well with the transcriptomic alterations after 24 h, whereas the
metabolic alterations after 24 h of treatment failed to correlate
with the transcriptomic data, suggesting that MEHP may induce
earlier transcriptomic alterations.
To further explore this hypothesis, we performed comple-
mentarytranscriptomicexperimentsatearliertimepointsandwe
assessed the expression of selected genes involved in key
adipocyte metabolic processes (e.g., diﬀerentiation, glyceroneo-
genesis, fatty acid synthesis...) after 4, 8, and 24 h of treatment
with MEHP (Figure 4). At 24 h of treatment with MEHP, most
of the tested genes were signiﬁcantly upregulated, which
Figure 2.
1H NMR-based metabonomic investigation MEHP eﬀects on human adipocytes. (A) Representative
1H NMR spectra (600 MHz) derived
from anaqueousextract ofhuman adipocytes. (B)Plot ofO-PLS-DA coeﬃcientsrelated to thediscrimination between
1HNMR spectra from aqueous
extractsofhumanadipocytestreatedwithMEHP(n=5,top)vs.DMSO(n=5,bottom)for48h.O-PLS-DAparameters:R
2X=0.65,R
2Y=0.94,Q
2Y=
0.73,p=910
3, onepredictive andoneorthogonal component. (C) Representative
1HNMRspectra (600MHz)derived fromanorganicextract of
human adipocytes. uk: unknown compound. (D) Plot of O-PLS-DA coeﬃcients related to the discrimination between
1H NMR spectra from organic
extractsofhumanadipocytestreatedwithMEHP(n=5,top)vs.DMSO(n=5,bottom)for48h.O-PLS-DAparameters:R
2X=0.93,R
2Y=0.98,Q
2Y=
0.68,p=0.03, onepredictive andtwoorthogonal components.Leu: leucine;Ile:isoleucine; Val: valine;Glu:glutamate; Gln:glutamine;Asp:aspartate;
TMA: trimethylamine; Cre: creatine; PC: phosphocholine; uk: unknown compound; PEA: phosphoethanolamine; NMN: N-methylnicotinamide;
NAD: nicotinamide adenine dinucleotide; Tyr: tyrosine; Phe: phenylalanine.
Figure 3. Intracellular triglycerides in human adipocytes. Human
preadipocytes (n = 5) were diﬀerentiated in vitro into adipocytes for
11 days and then treated with MEHP (100 μM) or DMSO (0.1%,
vehicle)for24or48h.Black:DMSO,red:MEHP.*:P<0.05compared
to DMSO-treated cells, Wilcoxon signed-rank test.5498 dx.doi.org/10.1021/pr200765v |J. Proteome Res. 2011, 10, 5493–5502
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conﬁrmedthemicroarray results. On thecontrary, at earlier time
points, only two genes were upregulated: the phosphoenolpyr-
uvate carboxykinase 1 (PCK1) and the pyruvate dehydrogenase
kinase 4 (PDK4), which encode the two main enzymes involved
in glyceroneogenesis.
23,24
Glyceroneogenesis is a metabolic pathway that converts
glucogenic precursors such as pyruvate or lactate into glycerol-
3-phosphate, which is then used for triglyceride synthesis
(Figure 5A). It has been demonstrated that the cytosolic
phosphoenolpyruvate carboxykinase (PEPCK-C), the protein
encodedbythePCK1gene,isthekeyenzymeinglyceroneogenesis.
25
Therefore, we assessed PEPCK-C protein expression after
MEHPtreatment.After18hofMEHPtreatment,thePEPCK-C
protein content was increased (Figure 5B). Furthermore,
glyceroneogenesis contributes to regulate the release of non-
esteriﬁed fatty acids (NEFA) from WAT in the circulation.
25
NEFA release from adipocytes indeed represents a balance
between fatty acid breakdown by lipolysis, and fatty acid
reesteriﬁcation into triglycerides, which are then released into
the bloodstream (Figure 5A). The eﬀects of MEHP on NEFA
reesteriﬁcation were investigated in human adipocytes by eval-
uating NEFA release into the culture medium during fasting. At
18hoftreatmentwithMEHPorDMSO,humanadipocyteswere
transferred for 3 h into a glucose-deprived culture medium, in
which the NEFA content was determined. NEFA release was
signiﬁcantly lower in MEHP-treated than in DMSO-treated
adipocytes (75 ( 13 μmol/g protein/h vs 100 ( 12 μmol/g
protein/h respectively, p = 0.03, Figure 5C).
’DISCUSSION
MEHP Enhances the Expression of Genes Associated with
PPARγ Activation in Human Adipocytes Differentiated in
Vitro
This study is the ﬁrst attempt to decipher the eﬀects of the
pollutant MEHP in a human model of WAT. We used an
untargeted combined transcriptomic
1H NMR-based metabo-
nomic approach to derive hypotheses about the mechanisms of
action of MEHP, which were then conﬁrmed using targeted
molecular methods. Transcriptomic proﬁling of human adipo-
cytes diﬀerentiated in vitro, established that 24 h of MEHP
treatment signiﬁcantly induced the expression of 12 genes
involved in “PPAR signaling pathway” (p =3 10
7, Figure 1,
SupplementaryTable3,SupportingInformation).Sevenofthese
12 genes have a known consensus sequence for PPAR binding
(PPAR response element) in their promoter: PCK1,
26 PDK4,
27
adipocyte diﬀerentiation related protein (ADRP),
28 lipoprotein
lipase(LPL),fatty-acidtranslocase(CD36),acylCoAsynthetase
1 (ACS1), and adiponectin (AdipoQ).
3
In keeping with our ﬁndings, studies in 3T3-L1 preadipocytes
showed that MEHP was a selective PPARγ activator.
6 In this
Figure 5. MEHP induced early metabolic alterations in human adipo-
cytes. (A) General description of the glyceroneogenesis and NEFA
reesteriﬁcation pathways in adipocytes (adapted from ref 25). (B)
PEPCK-C protein expression in human adipocytes treated with MEHP
(100 μM) or DMSO (0.1%) for 18 h. Representative Western blot. (C)
NEFA release in the culture medium of human adipocytes treated with
MEHP (100 μM) or DMSO (0.1%) for 18 h and fasted for 3 h. Results
represent a mean ( SEM for three replicates per individual (n = 5). *:
P < 0.05 compared to DMSO-treated cells, Wilcoxon signed-rank test.
Figure 4. MEHP induced early transcriptomic alterations in human
adipocytes. mRNA expression of genes involved in adipocyte diﬀeren-
tiation (A), glycerol metabolism (B), and other lipid-related metabolic
pathways (C) in MEHP-treated (100 μM) or DMSO-treated (0.1%)
human adipocytes. Data represent fold changes compared to DMSO-
treatedhumanadipocytes(mean(SEM,n=5).*:P<0.05,**:p<0.01
compared to DMSO-treated cells, Wilcoxon signed-rank test.5499 dx.doi.org/10.1021/pr200765v |J. Proteome Res. 2011, 10, 5493–5502
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murine cell line, MEHP induced the selective recruitment of
transcription cofactors by PPARγ, leading to induction of the
expression of a restricted subgroup of genes compared to
treatment with rosiglitazone, a full agonist of PPARγ. For
example, in 3T3-L1 preadipocytes, 10 days of MEHP treatment
induced the expression of adipoQ, CD36, ACS1, LPL, fatty acid
binding protein 4 (FABP4), cAMP element binding protein
alpha (CEBPα), and liver X receptor alpha (LRXα), whereas
rosiglitazone but not MEHP induced the expression of glycerol
kinase (GlyK) and oxidized low density lipoprotein receptor 1
(Olr1). This selective gene activation indicated that MEHP-
induced PPARγ target gene expression depended on the pro-
motercontext.Thisworkin3T3-L1cellsalsohighlightedthefact
that PPARγ transactivation by MEHP diﬀered according to the
analyzed cell line, which emphasizes the importance of conﬁrm-
ing these results in human cells, where the cellular coregulator
equipment might diﬀer. Using human adipocytes diﬀerentiated
in vitro, we observed a similar gene induction pattern after
MEHP treatment as in 3T3-L1 preadipocytes, i.e., induction of
the expression of FABP4, adipoQ, CD36, ACS1, LPL, CEBPα,
and LRXα genes but not of GlyK or Olr1 genes (Supplementary
Table 2, Supporting Information, Figure 4). However, in pre-
vious studies GlyK and Olr1 were activated by full agonists of
PPARγ in human adipocytes.
29,30 Thus, our results showed a
restricted gene induction proﬁle in MEHP-treated human adi-
pocytescomparedtofullPPARγagonists,indicatingthatMEHP
might be a selective PPARγ activator in human adipocytes.
MEHP Has a Pro-Differentiating Effect on Human Adipo-
cytes Differentiated in Vitro
PPARγisakeyregulator ofadipogenesis,theprocessthrough
which ﬁbroblast-like preadipocytes are converted into mature
adipocytes. In 3T3-L1 murine preadipocytes, MEHP-dependent
PPARγ activation promotes adipogenesis.
6 In the present work,
humanpreadipocyteswereﬁrstdiﬀerentiatedinvitrofor11days.
Intracellular triglycerides accumulation, a phenotypic marker of
diﬀerentiation, increased linearly during in vitro diﬀerentiation
(Figure 3). Triglyceride accumulation peaked 11 days after the
hormonal induction of diﬀerentiation, and the cells were then
treated with MEHP for one or two additional days. Although a
largeproportionofcells(6070%)werealreadydiﬀerentiatedat
thisstage,onepossibilitywastheresumptionofdiﬀerentiationin
the remaining preadipocytes.
Adipocyte diﬀerentiation is a very complex phenomenon that
converts ﬁbroblastic preadipocytes into mature adipocytes. This
process involves dramatic increases in triglyceride content,
drastic morphologic changes, and enhanced transcription of
adipocyte-speciﬁc genes.
31 In the present work, MEHP treat-
ment was associated with numerous transcriptomic alterations
conﬁrming that MEHP induced further diﬀerentiation of hu-
mans adipocytes diﬀerentiated in vitro. First, a well-described
hallmark of the adipogenesis process is the dramatic alteration in
cellshapeasthecellsconvertfromaﬁbroblastictoasphericalcell
shape. These morphological modiﬁcations occur simultaneously
with changes in the levels and types of extracellular matrix
components.
31 Here, we showed that MEHP treatment for 24 h
disturbed genes linked to “actin cytoskeleton regulation” and
“extracellularmatrix”(Figure1),indicatinganeﬀectoncellshape
and on interactions of cells with the extracellular matrix. For
instance, MEHP regulated the expression of two collagen genes
(COL4A6 *1.35, COL8A6 *-1.56, Supplementary Table 2,
Supporting Information). This switch in the expression of
collagen genes is a well-described event in adipogenesis.
31
Second, MEHP enhanced the expression of genes involved in
all metabolic pathways leading to triglyceride synthesis and
storage in human adipocytes: channeling and transport of fatty
acids (LPL, CD36, FABPs), production of glycerol-3-phosphate
(glycerol-3Pdehydrogenase(G3PDH),PCK1)andoffattyacid-
CoA esters (acylCoA synthase 2 (ACSF2), acylCoA synthase
long chain 3 (ACSL3) and ACSL5), and de novo lipogenesis
(acetylCoA carboxylase (ACCb), fatty acid synthase (FAS))
(Supplementary Table 2, Supporting Information).
In addition to these transcriptomic alterations, metabolic proﬁl-
ing revealed drastic changes in MEHP-treated cells. First, MEHP
increased the signals of protons involved in lipid double bonds, as
well as the aspartate and NAD contents (Figure 2). All these
metabolic changes have been reported previously during the
diﬀerentiationof3T3-L1preadipocytestoadipocytes.
3234Indeed,
fatty acid desaturation and aspartate transfer for putrescine synth-
esis were previously shown to be required for 3T3-L1 conversion
into adipocytes.
35,36 Second, MEHP decreased the intracellular
concentrations of lactate and glutamine, possibly via increased use
of these substrates for de novo lipogenesis.
37,38 Finally,
1HN M R -
based metabolic proﬁling, as well as subsequent enzymatic assays,
demonstratedthatafter48hoftreatment,MEHPfurtherincreased
the intracellular triglyceride level (Figure 3). Altogether, these
results demonstrate that MEHP had a pro-diﬀerentiating eﬀect
on human adipocytes diﬀerentiated in vitro.
MEHP Activated Glyceroneogenesis and Enhanced NEFA
Reesterification Early in Mature Human Adipocytes
Interestingly, early modulations in the metabolic proﬁles of
MEHP-treated human adipocytes occurred prior to the increase
inintracellulartriglycerides.Inaddition,at24hoftreatmentwith
MEHP, untargeted statistical integration of both transcriptomic
andmetabonomicproﬁlesrevealedpoorcorrelations.Thisresult
suggested that MEHP induced early modulation of gene expres-
sioninhumanadipocytes,independentlyfromthediﬀerentiation
process. This hypothesis was conﬁrmed by the strong and
selective induction of twogenes, PCK1 and PDK4, at only 4 h of
treatment with MEHP (Figure 4). PDK4 inhibits the activity of
the pyruvate dehydrogenase complex, which is involved in the
synthesisofacetyl-coAfrompyruvate.PDK4inductiontherefore
contributestoalterthepyruvatetowardoxaloacetateproduction.
PEPCK-C, the product of PCK1, synthesizes phosphoenolpyr-
uvate from oxaloacetate. Therefore, in WAT, combined activa-
tionofPCK1andPDK4genesresults intheredistributionofthe
pyruvateﬂuxtowardglyceroneogenesis.
24Aspreviouslydiscussed,
glyceroneogenesisisametabolicpathwayenhancedduringfasting
that converts glucogenic precursors such as pyruvate, lactate, or
aminoacidsintoglycerol-3-phosphate,whichissubsequentlyused
for triglyceride synthesis (Figure 5A). Here, glyceroneogenesis
activation by MEHP in human adipocytes was further conﬁrmed
bytheobservationthatMEHPincreasedPEPCK-Cproteinlevels.
Since PEPCK-C activity correlates directly with its expression
level,
39,40 this observation reﬂected an increased glyceroneogenic
ﬂux in MEHP-treated human adipocytes.
Furthermore, glyceroneogenesis contributes to regulate NEFA
release from WAT to the circulation. NEFA release from adipo-
cytes results from a balance between fatty acid breakdown by
lipolysis and fatty acid reesteriﬁcation into triglycerides, which are
then released into the bloodstream. Fatty acid reesteriﬁcation
accounts for a large proportion of lipolytically derived NEFA
(3070%)andthereforerequiresglycerol-3-phosphatesynthesis,5500 dx.doi.org/10.1021/pr200765v |J. Proteome Res. 2011, 10, 5493–5502
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which under fasting conditions originates from glyceroneogenesis
(Figure 5A). In the present work, we demonstrated that NEFA
release was reduced in MEHP-treated adipocytes after fasting.
This change might also result from a decrease in lipolysis or β-
oxidation.However,atearlytimepoints,wefoundnodecreasesin
the expression of genes involved inlipolysis, such astheadipocyte
triglyceride lipase (ATGL) or the hormone-sensitive lipase
(HSL), or in β-oxidation, such as the carnitine palmitoyl transfer-
ase1(CPT1).Similarly,arecentstudyshowednoeﬀectofDEHP
on lipolysis in rat adipose tissue.
41 Altogether, our results indicate
that more NEFAwere reesteriﬁedintotriglycerides under MEHP
treatment, for which glycerol backbone was provided by the
concomitant enhancement of glyceroneogenesis.
Finally, it has been demonstrated that PEPCK-C was
expressedonlyinmature adipocytesandthatPPARγwas unable
toactivatePCK1inpreadipocytes.
42Therefore,weconcludethat
PCK1 induction and thesubsequentincreasesinglyceroneogen-
esis and NEFA reesteriﬁcation observed in human adipocytes
diﬀerentiated in vitro after MEHP treatment occurred in the
mature adipocytes present in the cell culture.
MEHP Exposure and Expected Consequences for Humans
Although the human exposure to DEHP is ubiquitous, plasma
levels of DEHP and MEHP are thought to remain generally low
because of rapid urinary excretion.
43 Plasmatic concentrations of
38 mg/L (∼100 μM) DEHP and of about 1.37 μg/mL(∼3 μM)
MEHP have been measured in healthy individuals.
44,45 However,
several parameters such as daily use of cosmetics, mouthing
behavior in children, neonatal intensive care, frequent blood
transfusion or dialysis can increase phthalate exposure 414-fold
compared to control populations.
4648 Furthermore, DEHP is a
lipophilic compoundthat can accumulate in WAT.
44 Wefoundno
data on MEHP accumulation in WAT. However, exposure data
suggest that, under certain circumstances, MEHP levels in plasma
and WAT may reach 100 μM, the concentration for which we
observedmetaboliceﬀectsinhumanpreadipocytesandadipocytes.
Inthiswork,wehaveshownthatMEHPincreasedthetriglyceride
content in human adipocytes diﬀerentiated in vitro, which may
be explained by, at least, two concomitant mechanisms: an early
increase in glyceroneogenesis and NEFA reesteriﬁcation occur-
ring in mature adipocytes, followed by diﬀerentiation of the
remaining preadipocytes. In previous studies, both mechanisms
were activated in animal and human WAT by other PPARγ
agonists, such as the antidiabetic drugs thiazolidinediones.
22,49
Both mechanisms contribute to the global improvement in
carbohydrate and lipid homeostasis observed during thiazolidi-
nedione treatment. However, they also both result in increased
triglyceride accumulation in WAT and are thought to participate
in the weight-gain promoting eﬀect of these drugs. These
mechanisms may thus contribute to the suspected obesogen
eﬀect of MEHP and of other phthalates capable of activating
PPARγ. Epidemiological studies have indeed shown a positive
correlation between urinary MEHP concentrations and waist
circumference in healthy men
50 and between other phthalate
metabolites and body mass index.
51
In addition, glyceroneogenesis activation by MEHP may also
interfere more generally with energy homeostasis in exposed
populations. The eﬀect of PEPCK-C in WAT on both glycer-
oneogenesis and reesteriﬁcation of NEFA to triglycerides is
crucial to prevent diabetes. PEPCK-C dysregulation interferes
with the triglyceride/fatty acid cycle, which regulates lipid
synthesis and transport between WAT and the liver, leading to
the development of insulin resistance in mice.
52 In another study,
Franckhauser et al. demonstrated that transgenic mice overexpres-
sing PEPCK-C in WAT remained insulin sensitive under ahigh-fat
dietbutdevelopedsevereobesityandweremorehyperinsulinemic,
glucose intolerant, and insulin resistant than wild-type controls.
53
Thus, PEPCK-C overexpression in adipose tissue increased the
susceptibility to diet-induced obesity and insulin resistance. These
results, together with our present work, suggest that phthalate
exposure might be of particular concern in populations already
susceptible to insulin resistance because of an unbalanced diet.
’CONCLUSION
ThisstudyinahumanWATmodelprovidestheﬁrstevidence
that the environmental pollutant MEHP promotes triglyceride
storage by altering the metabolism of both preadipocytes and
mature adipocytes. The earliest eﬀects of MEHP were increases
in glyceroneogenesis and NEFA reesteriﬁcation in mature adi-
pocytes, which interfered with the regulation of fatty acid release
byhumanWAT.Afteralongertreatmenttime,MEHPhadapro-
diﬀerentiating eﬀect on the preadipocytes remaining in the cell
cultures. These results provide convincing new evidence that
MEHP interferes with endogenous lipid metabolism in human
WAT and should therefore be considered as a potential obeso-
gen, as well as a more general metabolic disruptor.
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